GLAXOSMITHKLINE PHARMACEUTICALS
|
The Current P/S Ratio of GLAXOSMITHKLINE PHARMACEUTICALS is 10.64.
| Share Price | ₹2,483.6 | Oct 30,2026 |
| Market Cap | ₹42,071.3 Cr | |
| Sales-TTM | ₹3,954.9 Cr | TTM-Consolidated Results |
| Price/Sales | 10.64x | Calculated as Market Cap/Sales |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PS (Price/Sales) ratio of GLAXOSMITHKLINE PHARMACEUTICALS
P/S =
Market Capitalization
/
Sales
or, using per-share numbers:
P/S = Stock Price / Sales Per Share
Current Market Cap [ ₹42,071.3 Cr] as on Oct 30,2026
(/) Sales [ ₹3,954.9 Cr] based on TTM-Consolidated Results
(=) P/S Ratio [ 10.64x ]
Thus, for GLAXOSMITHKLINE PHARMACEUTICALS , the investors are currently willing to pay '10.64 times sales' to own 1 share of the company.
PS Multiples are one of the most widely used valuation multiple in the industry.
P/S ratios can be a reliable benchmark to compare companies with negative earnings or book value.
You may also explore Price to Earnings ratio or Price to Book ratio of GLAXOSMITHKLINE PHARMACEUTICALS !
The chart below summarizes the trend in P/S Ratio of GLAXOSMITHKLINE PHARMACEUTICALS over the last five years.
Historical PS (Price/Sales) ratio chart of GLAXOSMITHKLINE PHARMACEUTICALS
PS Ratio Performance Analysis for GLAXOSMITHKLINE PHARMACEUTICALS
- GLAXOSMITHKLINE PHARMACEUTICALS 's p/e ratio for fiscal years ending Mar2026 to Mar2022 averaged 9.63x.
- GLAXOSMITHKLINE PHARMACEUTICALS 's operated at median p/e ratio of 9.53x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, GLAXOSMITHKLINE PHARMACEUTICALS 's p/e ratio peaked in Mar2025 at 13x.
- GLAXOSMITHKLINE PHARMACEUTICALS 's p/e ratio hit its five-year low in Mar2023 of 6.9x.
How does GLAXOSMITHKLINE PHARMACEUTICALS 's P/S Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Sales (Cr) | PS Ratio | Market Cap (Cr) |
|---|---|---|---|
| GLAXOSMITHKLINE PHARMACEUTICALS | 3,954.9 | 10.64 | 42,071.3 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 61,630.9 | 6.92 | 426,662.0 |
| DIVIS LABORATORIES LTD | 11,230.0 | 22.97 | 257,903.0 |
| TORRENT PHARMACEUTICALS LTD | 17,400.0 | 10.13 | 176,306.0 |
| CIPLA LTD | 28,138.9 | 3.96 | 111,489.0 |
| DR REDDYS LABORATORIES LTD | 33,097.4 | 3.41 | 112,699.0 |
| MANKIND PHARMA LTD | 15,378.6 | 6.68 | 102,797.0 |
| LUPIN LTD | 29,966.6 | 3.07 | 91,870.2 |
| ZYDUS LIFESCIENCES LTD | 28,591.7 | 4.34 | 124,089.0 |
| AUROBINDO PHARMA LTD | 34,935.3 | 2.76 | 96,536.9 |
| LAURUS LABS LTD | 7,822.5 | 16.52 | 129,243.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PS Analysis vs GLAXOSMITHKLINE PHARMACEUTICALS 's P/S Ratio
| Top 10 Industry Peers | PS Ratio |
|---|---|
| Min industry PS | 2.76x |
| Max industry PS | 22.97x |
| Median industry PS | 6.68x |
| Average industry PS | 8.31x |
You may also like the below Video Courses